Liquid Biopsy Market Size, Share and Growth Outlook 2026: By Product (Consumables, Instruments, Services), By Biomarker Type, By Sample Type, By Application, By End User, Companies to 2034.
The global Liquid Biopsy Market size is forecast to increase from $7.19 Billion in 2026 to $16.81 Billion in 2034 at a CAGR of 11.2% between 2026 and 2034.
The Liquid Biopsy market report provides detailed analysis and outlook of Liquid Biopsy segments including By Product (Consumables, Instruments, Services ), By Biomarker Type (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Cell-free DNA (cfDNA), Extracellular Vesicles, Others), By Sample Type (Blood, Urine, Others ), By Application (Cancer Diagnosis, Treatment Monitoring, Recurrence Monitoring, Non-cancer Applications ), By End User (Hospitals, Cancer Institutes, Academic and Research Institutes, Diagnostic Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Liquid Biopsy Industry Overview
Multi-Cancer Detection and Residual Disease Monitoring Drive Market Expansion
The liquid biopsy industry is rapidly advancing as healthcare systems adopt blood-based diagnostics for cancer screening, treatment monitoring, molecular profiling, and minimal residual disease assessment. Compared with conventional tissue biopsies, liquid biopsy technologies offer minimally invasive sampling, repeat testing capability, and broader insight into tumor dynamics across multiple disease stages. Industry innovation is increasingly focused on multi-cancer early detection, molecular residual disease tracking, therapy response assessment, and population-scale screening applications. Growing adoption among oncology providers and expanding clinical evidence are strengthening the role of liquid biopsy technologies across precision medicine and cancer management workflows.
Minimal Residual Disease Monitoring Gains Clinical Momentum
Healthcare providers are increasingly utilizing liquid biopsy platforms to monitor treatment effectiveness and detect residual cancer following therapy. Guardant Health expanded deployment of its Guardant Reveal assay for therapy response evaluation and minimal residual disease monitoring. The company reported strong adoption across its oncology diagnostics portfolio, with approximately 79,000 clinical oncology tests performed during the reporting period, representing a 38% increase compared with prior-year volumes. Growth in testing utilization reflects increasing clinical confidence in blood-based monitoring technologies that provide actionable information regarding disease progression, recurrence risk, and treatment response without requiring invasive tissue sampling procedures.
Multi-Cancer Screening Platforms Expand Preventive Oncology Strategies
Developers are broadening liquid biopsy applications beyond established oncology monitoring into population-level cancer screening. Exact Sciences initiated commercial deployment of the Cancerguard® Multi-Cancer Early Detection platform targeting adults between 50 and 84 years of age without recent cancer histories. The assay analyzes circulating molecular signals associated with cancer types representing more than 80% of diagnosed malignancies. Clinical modeling indicates that pairing molecular detection with imaging-guided diagnostic pathways can reduce downstream diagnostic procedures by approximately 30% compared with standalone molecular screening approaches. These advancements demonstrate how liquid biopsy technologies are increasingly supporting earlier cancer detection and more efficient diagnostic workflows.
Molecular Analytics Strengthen Precision Oncology Applications
The liquid biopsy industry continues to expand through increasingly sophisticated molecular analysis capabilities. Exact Sciences scheduled presentation of updated clinical findings covering its Molecular Residual Disease platforms and multi-cancer detection algorithms. These initiatives complement the commercial launch of Cologuard Plus, which combines DNA methylation analysis with protein biomarker verification to achieve 94% sensitivity and 91% specificity. The integration of multiple molecular markers, advanced analytics, and residual disease monitoring technologies reflects a broader shift toward comprehensive precision oncology platforms capable of supporting screening, diagnosis, treatment selection, and long-term disease surveillance within a unified testing ecosystem.
Liquid Biopsy Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Liquid Biopsy market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Guardant Health, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, QIAGEN N.V., Thermo Fisher Scientific Inc., Exact Sciences Corporation, NeoGenomics Laboratories, Inc., Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., ANGLE plc. The Liquid Biopsy market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Liquid Biopsy industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Liquid Biopsy industry include- Guardant Health, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, QIAGEN N.V., Thermo Fisher Scientific Inc., Exact Sciences Corporation, NeoGenomics Laboratories, Inc., Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., ANGLE plc. The Liquid Biopsy market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Liquid Biopsy Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Liquid Biopsy market remains one of the strongest-performing segments in the country.
The US Liquid Biopsy Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Liquid Biopsy market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Liquid Biopsy industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Liquid Biopsy markets
Canada's strong Liquid Biopsy sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Liquid Biopsy market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Liquid Biopsy Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Liquid Biopsy market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Liquid Biopsy population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Liquid Biopsy industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Liquid Biopsy market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Liquid Biopsy sales through 2034
France Liquid Biopsy companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Liquid Biopsy Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Liquid Biopsy distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Liquid Biopsy Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Liquid Biopsy market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Liquid Biopsy industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Liquid Biopsy industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Liquid Biopsy Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Liquid Biopsy market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Liquid Biopsy market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Liquid Biopsy Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Liquid Biopsy Market Segmentation
By Product
Consumables
Instruments
Services
By Biomarker Type
Circulating Tumor Cells (CTCs)
Circulating Tumor DNA (ctDNA)
Cell-free DNA (cfDNA)
Extracellular Vesicles
Others
By Sample Type
Blood
Urine
Others
By Application
Cancer Diagnosis
Treatment Monitoring
Recurrence Monitoring
Non-cancer Applications
By End User
Hospitals
Cancer Institutes
Academic and Research Institutes
Diagnostic Centers
Leading Companies in Liquid Biopsy Industry (2026)
Guardant Health, Inc.
Illumina, Inc.
F. Hoffmann-La Roche Ltd
QIAGEN N.V.
Thermo Fisher Scientific Inc.
Exact Sciences Corporation
NeoGenomics Laboratories, Inc.
Bio-Rad Laboratories, Inc.
Myriad Genetics, Inc.
ANGLE plc
Countries Included
The Liquid Biopsy market report provides detailed analysis and outlook of Liquid Biopsy segments including By Product (Consumables, Instruments, Services ), By Biomarker Type (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Cell-free DNA (cfDNA), Extracellular Vesicles, Others), By Sample Type (Blood, Urine, Others ), By Application (Cancer Diagnosis, Treatment Monitoring, Recurrence Monitoring, Non-cancer Applications ), By End User (Hospitals, Cancer Institutes, Academic and Research Institutes, Diagnostic Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Liquid Biopsy Industry Overview
Multi-Cancer Detection and Residual Disease Monitoring Drive Market Expansion
The liquid biopsy industry is rapidly advancing as healthcare systems adopt blood-based diagnostics for cancer screening, treatment monitoring, molecular profiling, and minimal residual disease assessment. Compared with conventional tissue biopsies, liquid biopsy technologies offer minimally invasive sampling, repeat testing capability, and broader insight into tumor dynamics across multiple disease stages. Industry innovation is increasingly focused on multi-cancer early detection, molecular residual disease tracking, therapy response assessment, and population-scale screening applications. Growing adoption among oncology providers and expanding clinical evidence are strengthening the role of liquid biopsy technologies across precision medicine and cancer management workflows.
Minimal Residual Disease Monitoring Gains Clinical Momentum
Healthcare providers are increasingly utilizing liquid biopsy platforms to monitor treatment effectiveness and detect residual cancer following therapy. Guardant Health expanded deployment of its Guardant Reveal assay for therapy response evaluation and minimal residual disease monitoring. The company reported strong adoption across its oncology diagnostics portfolio, with approximately 79,000 clinical oncology tests performed during the reporting period, representing a 38% increase compared with prior-year volumes. Growth in testing utilization reflects increasing clinical confidence in blood-based monitoring technologies that provide actionable information regarding disease progression, recurrence risk, and treatment response without requiring invasive tissue sampling procedures.
Multi-Cancer Screening Platforms Expand Preventive Oncology Strategies
Developers are broadening liquid biopsy applications beyond established oncology monitoring into population-level cancer screening. Exact Sciences initiated commercial deployment of the Cancerguard® Multi-Cancer Early Detection platform targeting adults between 50 and 84 years of age without recent cancer histories. The assay analyzes circulating molecular signals associated with cancer types representing more than 80% of diagnosed malignancies. Clinical modeling indicates that pairing molecular detection with imaging-guided diagnostic pathways can reduce downstream diagnostic procedures by approximately 30% compared with standalone molecular screening approaches. These advancements demonstrate how liquid biopsy technologies are increasingly supporting earlier cancer detection and more efficient diagnostic workflows.
Molecular Analytics Strengthen Precision Oncology Applications
The liquid biopsy industry continues to expand through increasingly sophisticated molecular analysis capabilities. Exact Sciences scheduled presentation of updated clinical findings covering its Molecular Residual Disease platforms and multi-cancer detection algorithms. These initiatives complement the commercial launch of Cologuard Plus, which combines DNA methylation analysis with protein biomarker verification to achieve 94% sensitivity and 91% specificity. The integration of multiple molecular markers, advanced analytics, and residual disease monitoring technologies reflects a broader shift toward comprehensive precision oncology platforms capable of supporting screening, diagnosis, treatment selection, and long-term disease surveillance within a unified testing ecosystem.
Liquid Biopsy Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Liquid Biopsy market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Guardant Health, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, QIAGEN N.V., Thermo Fisher Scientific Inc., Exact Sciences Corporation, NeoGenomics Laboratories, Inc., Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., ANGLE plc. The Liquid Biopsy market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Liquid Biopsy industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Liquid Biopsy Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Liquid Biopsy companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Liquid Biopsy markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Liquid Biopsy industry include- Guardant Health, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, QIAGEN N.V., Thermo Fisher Scientific Inc., Exact Sciences Corporation, NeoGenomics Laboratories, Inc., Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., ANGLE plc. The Liquid Biopsy market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Liquid Biopsy Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Liquid Biopsy market remains one of the strongest-performing segments in the country.
The US Liquid Biopsy Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Liquid Biopsy market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Liquid Biopsy industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Liquid Biopsy markets
Canada's strong Liquid Biopsy sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Liquid Biopsy market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Liquid Biopsy Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Liquid Biopsy market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Liquid Biopsy population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Liquid Biopsy industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Liquid Biopsy market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Liquid Biopsy sales through 2034
France Liquid Biopsy companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Liquid Biopsy Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Liquid Biopsy distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Liquid Biopsy Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Liquid Biopsy market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Liquid Biopsy industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Liquid Biopsy industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Liquid Biopsy Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Liquid Biopsy market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Liquid Biopsy market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Liquid Biopsy Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Liquid Biopsy Market Segmentation
By Product
Consumables
Instruments
Services
By Biomarker Type
Circulating Tumor Cells (CTCs)
Circulating Tumor DNA (ctDNA)
Cell-free DNA (cfDNA)
Extracellular Vesicles
Others
By Sample Type
Blood
Urine
Others
By Application
Cancer Diagnosis
Treatment Monitoring
Recurrence Monitoring
Non-cancer Applications
By End User
Hospitals
Cancer Institutes
Academic and Research Institutes
Diagnostic Centers
Leading Companies in Liquid Biopsy Industry (2026)
Guardant Health, Inc.
Illumina, Inc.
F. Hoffmann-La Roche Ltd
QIAGEN N.V.
Thermo Fisher Scientific Inc.
Exact Sciences Corporation
NeoGenomics Laboratories, Inc.
Bio-Rad Laboratories, Inc.
Myriad Genetics, Inc.
ANGLE plc
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Liquid Biopsy Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Liquid Biopsy Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL LIQUID BIOPSY MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Liquid Biopsy Markets in 2026
3.2. Global Historic and Forecast Liquid Biopsy Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Liquid Biopsy Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Liquid Biopsy Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Liquid Biopsy Value Chain
CHAPTER 4- LIQUID BIOPSY MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Liquid Biopsy Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- LIQUID BIOPSY MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product
Consumables
Instruments
Services
By Biomarker Type
Circulating Tumor Cells (CTCs)
Circulating Tumor DNA (ctDNA)
Cell-free DNA (cfDNA)
Extracellular Vesicles
Others
By Sample Type
Blood
Urine
Others
By Application
Cancer Diagnosis
Treatment Monitoring
Recurrence Monitoring
Non-cancer Applications
By End User
Hospitals
Cancer Institutes
Academic and Research Institutes
Diagnostic Centers
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA LIQUID BIOPSY MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Liquid Biopsy Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Liquid Biopsy Market Trends and Growth Opportunities to 2034
7.5. North America Liquid Biopsy Market Size Outlook by Type
7.6. North America Liquid Biopsy Market Size Outlook by Application
7.7. North America Liquid Biopsy Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Liquid Biopsy Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Liquid Biopsy Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Liquid Biopsy Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Liquid Biopsy Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Liquid Biopsy Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Liquid Biopsy Companies
CHAPTER 8- EUROPE LIQUID BIOPSY MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Liquid Biopsy Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Liquid Biopsy Market Trends and Growth Opportunities to 2034
8.5. Europe Liquid Biopsy Market Size Outlook by Type
8.6. Europe Liquid Biopsy Market Size Outlook by Application
8.7. Europe Liquid Biopsy Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Liquid Biopsy Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Liquid Biopsy Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Liquid Biopsy Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Liquid Biopsy Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Liquid Biopsy Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Liquid Biopsy Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Liquid Biopsy Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Liquid Biopsy Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Liquid Biopsy Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Liquid Biopsy Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Liquid Biopsy Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Liquid Biopsy Companies
CHAPTER 9- ASIA PACIFIC LIQUID BIOPSY MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Liquid Biopsy Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Liquid Biopsy Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Liquid Biopsy Market Size Outlook by Type
9.6. Asia Pacific Liquid Biopsy Market Size Outlook by Application
9.7. Asia Pacific Liquid Biopsy Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Liquid Biopsy Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Liquid Biopsy Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Liquid Biopsy Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Liquid Biopsy Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Liquid Biopsy Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Liquid Biopsy Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Liquid Biopsy Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Liquid Biopsy Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Liquid Biopsy Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Liquid Biopsy Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Liquid Biopsy Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Liquid Biopsy Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA LIQUID BIOPSY MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Liquid Biopsy Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Liquid Biopsy Market Trends and Growth Opportunities to 2034
10.5. South and Central America Liquid Biopsy Market Size Outlook by Type
10.6. South and Central America Liquid Biopsy Market Size Outlook by Application
10.7. South and Central America Liquid Biopsy Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Liquid Biopsy Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Liquid Biopsy Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Liquid Biopsy Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Liquid Biopsy Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Liquid Biopsy Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Liquid Biopsy Companies
CHAPTER 11- MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Liquid Biopsy Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Liquid Biopsy Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Liquid Biopsy Market Size Outlook by Type
11.6. Middle East and Africa Liquid Biopsy Market Size Outlook by Application
11.7. Middle East and Africa Liquid Biopsy Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Liquid Biopsy Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Liquid Biopsy Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Liquid Biopsy Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Liquid Biopsy Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Liquid Biopsy Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Liquid Biopsy Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Liquid Biopsy Industry
Guardant Health, Inc.
Illumina, Inc.
F. Hoffmann-La Roche Ltd
QIAGEN N.V.
Thermo Fisher Scientific Inc.
Exact Sciences Corporation
NeoGenomics Laboratories, Inc.
Bio-Rad Laboratories, Inc.
Myriad Genetics, Inc.
ANGLE plc
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Liquid Biopsy Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Liquid Biopsy Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL LIQUID BIOPSY MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Liquid Biopsy Markets in 2026
3.2. Global Historic and Forecast Liquid Biopsy Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Liquid Biopsy Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Liquid Biopsy Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Liquid Biopsy Value Chain
CHAPTER 4- LIQUID BIOPSY MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Liquid Biopsy Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- LIQUID BIOPSY MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product
Consumables
Instruments
Services
By Biomarker Type
Circulating Tumor Cells (CTCs)
Circulating Tumor DNA (ctDNA)
Cell-free DNA (cfDNA)
Extracellular Vesicles
Others
By Sample Type
Blood
Urine
Others
By Application
Cancer Diagnosis
Treatment Monitoring
Recurrence Monitoring
Non-cancer Applications
By End User
Hospitals
Cancer Institutes
Academic and Research Institutes
Diagnostic Centers
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA LIQUID BIOPSY MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Liquid Biopsy Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Liquid Biopsy Market Trends and Growth Opportunities to 2034
7.5. North America Liquid Biopsy Market Size Outlook by Type
7.6. North America Liquid Biopsy Market Size Outlook by Application
7.7. North America Liquid Biopsy Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Liquid Biopsy Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Liquid Biopsy Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Liquid Biopsy Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Liquid Biopsy Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Liquid Biopsy Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Liquid Biopsy Companies
CHAPTER 8- EUROPE LIQUID BIOPSY MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Liquid Biopsy Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Liquid Biopsy Market Trends and Growth Opportunities to 2034
8.5. Europe Liquid Biopsy Market Size Outlook by Type
8.6. Europe Liquid Biopsy Market Size Outlook by Application
8.7. Europe Liquid Biopsy Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Liquid Biopsy Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Liquid Biopsy Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Liquid Biopsy Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Liquid Biopsy Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Liquid Biopsy Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Liquid Biopsy Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Liquid Biopsy Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Liquid Biopsy Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Liquid Biopsy Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Liquid Biopsy Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Liquid Biopsy Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Liquid Biopsy Companies
CHAPTER 9- ASIA PACIFIC LIQUID BIOPSY MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Liquid Biopsy Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Liquid Biopsy Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Liquid Biopsy Market Size Outlook by Type
9.6. Asia Pacific Liquid Biopsy Market Size Outlook by Application
9.7. Asia Pacific Liquid Biopsy Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Liquid Biopsy Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Liquid Biopsy Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Liquid Biopsy Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Liquid Biopsy Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Liquid Biopsy Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Liquid Biopsy Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Liquid Biopsy Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Liquid Biopsy Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Liquid Biopsy Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Liquid Biopsy Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Liquid Biopsy Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Liquid Biopsy Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA LIQUID BIOPSY MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Liquid Biopsy Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Liquid Biopsy Market Trends and Growth Opportunities to 2034
10.5. South and Central America Liquid Biopsy Market Size Outlook by Type
10.6. South and Central America Liquid Biopsy Market Size Outlook by Application
10.7. South and Central America Liquid Biopsy Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Liquid Biopsy Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Liquid Biopsy Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Liquid Biopsy Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Liquid Biopsy Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Liquid Biopsy Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Liquid Biopsy Companies
CHAPTER 11- MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Liquid Biopsy Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Liquid Biopsy Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Liquid Biopsy Market Size Outlook by Type
11.6. Middle East and Africa Liquid Biopsy Market Size Outlook by Application
11.7. Middle East and Africa Liquid Biopsy Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Liquid Biopsy Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Liquid Biopsy Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Liquid Biopsy Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Liquid Biopsy Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Liquid Biopsy Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Liquid Biopsy Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Liquid Biopsy Industry
Guardant Health, Inc.
Illumina, Inc.
F. Hoffmann-La Roche Ltd
QIAGEN N.V.
Thermo Fisher Scientific Inc.
Exact Sciences Corporation
NeoGenomics Laboratories, Inc.
Bio-Rad Laboratories, Inc.
Myriad Genetics, Inc.
ANGLE plc
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
